Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 22Lymphoma, Follicular 14Lymphoma 12Lymphoma, B-Cell, Marginal Zone 11Lymphoma, Mantle-Cell 10Lymphoma, Non-Hodgkin 8Lymphoma, Large B-Cell, Diffuse 7Neoplasms 4Lymphoma, B-Cell 4Burkitt Lymphoma 4Recurrence 3Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Neoplasm, Residual 1Melanoma 1Mature B-cell Malignancies 1Lymphoproliferative Disorders 1Lymphatic Diseases 1Leukemia, Hairy Cell 1Leukemia, B-Cell 1Leukemia 1Heart Failure 1Extensive Stage Small Cell Lung Cancer 1Dendritic Cell Sarcoma, Interdigitating 1Cytokine Release Syndrome 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma 1

Interventions

obinutuzumab 1durvalumab 1ceralasertib 1Etoposide 1Cisplatin 1Carboplatin 1AMG 757 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Extensive Stage Small Cell Lung Cancer × obinutuzumab × Clear all
NCT07107490 2026-02-06

A PHASE I STUDY OF ALPS12 IN PATIENTS WITH EXTENSIVE STAGE SMALL CELL LUNG CANCER

Chugai Pharmaceutical

Phase 1 Recruiting
122 enrolled
Thoracic

Extensive Stage Small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡